The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials
Open accessAbstract
The rate of renal disease progression varies widely among patients with autosomal dominant polycystic kidney disease (ADPKD), necessitating optimal patient selection for enrollment into clinical trials. Patients from the Mayo Clinic Translational PKD Center with ADPKD (n=590) with computed tomography/magnetic resonance images and three or more eGFR measurements over ≥6 months were classified radiologically as typical (n=538) or atypical (n=52). Total kidney volume (TKV) was measured using stereology (TKVs) and ellipsoid equation (TKVe). Typical patients were randomly partitioned into development and internal validation sets and subclassified according to height-adjusted TKV (HtTKV) ranges for age (1A-1E, in increasing order). Consortium for Radiologic Imaging Study of PKD (CRISP) participants (n=173) were used for external validation. TKVe correlated strongly with TKVs, without systematic underestimation or overestimation. A longitudinal mixed regression model to predict eGFR decline showed that log2HtTKV and age significantly interacted with time in typical patients, but not in atypical patients. When 1A-1E classifications were used instead of log2HtTKV, eGFR slopes were significantly different among subclasses and, except for 1A, different from those in healthy kidney donors. The equation derived from the development set predicted eGFR in both validation sets. The frequency of ESRD at 10 years increased from subclass 1A (2.4%) to 1E (66.9%) in the Mayo cohort and from 1C (2.2%) to 1E (22.3%) in the younger CRISP cohort. Class and subclass designations were stable. An easily applied classification of ADPKD based on HtTKV and age should optimize patient selection for enrollment into clinical trials and for treatment when one becomes available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationAutosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citationYao, Q., Wu, M., Zhou, J., Zhou, M., Chen, D., Fu, L., Bian, R., Xing, X., Sun, L., Hu, X., et al. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000474961 · Cited by 847
Volume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807
Self-citationUnified Criteria for Ultrasonographic Diagnosis of ADPKD
Pei, Y., Obaji, J., Dupuis, A., Paterson, A. D., Magistroni, R., Dicks, E., Parfrey, P., Cramer, B., Coto, E., Torra, R., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050507 · Cited by 762
Comparison of phenotypes of polycystic kidney disease types 1 and 2
Hateboer, N., v Dijk, M. A., Bogdanova, N., Coto, E., Saggar-Malik, A. K., Millan, J. L. S., Torra, R., Breuning, M., & Ravine, D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03495-3 · Cited by 628
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Autosomal Dominant Polycystic Kidney Disease
Grantham, J. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0804458 · Cited by 543
Self-citationType of PKD1 Mutation Influences Renal Outcome in ADPKD
Cornec-Le Gall, E., Audrézet, M.-P., Chen, J.-M., Hourmant, M., Morin, M.-P., Perrichot, R., Charasse, C., Whebe, B., Renaudineau, E., Jousset, P., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070650 · Cited by 530
Chapman, A. B., Guay-Woodford, L. M., Grantham, J. J., Torres, V. E., Bae, K. T., Baumgarten, D. A., Kenney, P. J., King, B. F., Glockner, J. F., Wetzel, L. H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00185.x · Cited by 413
Self-citationKidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease
Chapman, A. B., Bost, J. E., Torres, V. E., Guay-Woodford, L., Bae, K. T., Landsittel, D., Li, J., King, B. F., Martin, D., Wetzel, L. H., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09500911 · Cited by 378
Self-citationHogan, M. C., Masyuk, T. V., Page, L. J., Kubly, V. J., Bergstralh, E. J., Li, X., Kim, B., King, B. F., Glockner, J., Holmes, D. R., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121291 · Cited by 333
Self-citationRossetti, S., Kubly, V. J., Consugar, M. B., Hopp, K., Roy, S., Horsley, S. W., Chauveau, D., Rees, L., Barratt, T. M., van't Hoff, W. G., et al. (2009) · Kidney International · doi:10.1038/ki.2008.686 · Cited by 300
Self-citationHarris, P. C., Bae, K. T., Rossetti, S., Torres, V. E., Grantham, J. J., Chapman, A. B., Guay-Woodford, L. M., King, B. F., Wetzel, L. H., Baumgarten, D. A., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080835 · Cited by 271
Self-citationRuggenenti, P., Remuzzi, A., Ondei, P., Fasolini, G., Antiga, L., Ene-Iordache, B., Remuzzi, G., & Epstein, F. H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00395.x · Cited by 270
Caroli, A., Perico, N., Perna, A., Antiga, L., Brambilla, P., Pisani, A., Visciano, B., Imbriaco, M., Messa, P., Cerutti, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61407-5 · Cited by 258
van Keimpema, L., Nevens, F., Vanslembrouck, R., van Oijen, M. G. H., Hoffmann, A. L., Dekker, H. M., de Man, R. A., & Drenth, J. P. H. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.052 · Cited by 257
Renal Volume Measurements: Accuracy and Repeatability of US Compared with That of MR Imaging
Bakker, J., Olree, M., Kaatee, R., de Lange, E. E., Moons, K. G. M., Beutler, J. J., & Beek, F. J. A. (1999) · Radiology · doi:10.1148/radiology.211.3.r99jn19623 · Cited by 248
Poggio, E. D., Rule, A. D., Tanchanco, R., Arrigain, S., Butler, R. S., Srinivas, T., Stephany, B. R., Meyer, K. H., Nurko, S., Fatica, R. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.11 · Cited by 217
A complete mutation screen of the ADPKD genes by DHPLC
Rossetti, S., Chauveau, D., Walker, D., Saggar-Malik, A., Winearls, C. G., Torres, V. E., & Harris, P. C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00326.x · Cited by 170
Self-citationSirolimus Therapy to Halt the Progression of ADPKD
Perico, N., Antiga, L., Caroli, A., Ruggenenti, P., Fasolini, G., Cafaro, M., Ondei, P., Rubis, N., Diadei, O., Gherardi, G., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121302 · Cited by 165
Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience
Higashihara, E., Torres, V. E., Chapman, A. B., Grantham, J. J., Bae, K. T., Watnick, T. J., Horie, S., Nutahara, K., Ouyang, J., Krasa, H. B., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03530411 · Cited by 152
Self-citationThe HALT Polycystic Kidney Disease Trials: Design and Implementation
Chapman, A. B., Torres, V. E., Perrone, R. D., Steinman, T. I., Bae, K. T., Miller, J. P., Miskulin, D. C., Rahbari-Oskoui, F. F., Masoumi, A., Hogan, M. C., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04310709 · Cited by 152
Self-citationO'Neill, W. C., Robbin, M. L., Bae, K. T., Grantham, J. J., Chapman, A. B., Guay‐Woodford, L. M., Torres, V. E., King, B. F., Wetzel, L. H., Thompson, P. A., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.026 · Cited by 113
Self-citationDeterminants of renal volume in autosomal-dominant polycystic kidney disease
Grantham, J. J., Cook, L. T., Torres, V. E., Bost, J. E., Chapman, A. B., Harris, P. C., Guay‐Woodford, L. M., & Bae, K. T. (2007) · Kidney International · doi:10.1038/sj.ki.5002624 · Cited by 108
Self-citationAnalysis of longitudinal data: Random coefficient regression modelling
Rutter, C. M., & Elashoff, R. M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131204 · Cited by 105
Imaging for the prognosis of autosomal dominant polycystic kidney disease
Bae, K. T., & Grantham, J. J. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.214 · Cited by 92
Self-citationDeterminants of Renal Disease Variability in ADPKD
Harris, P. C., & Rossetti, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2009.12.004 · Cited by 91
Self-citationConnor, A., Lunt, P. W., Dolling, C., Patel, Y., Meredith, A. L., Gardner, A., Hamilton, N., & Dudley, C. R. K. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02030.x · Cited by 45
Autosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele
Reiterová, J., Štekrová, J., Merta, M., Kotlas, J., Elišáková, V., Lněnička, P., Korabečná, M., Kohoutová, M., & Tesař, V. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-59 · Cited by 35
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Self-citationTolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Koch, G., Ouyang, J., McQuade, R. D., Blais, J. D., Czerwiec, F. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1710030 · Cited by 639
Self-citationAutosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Chapman, A. B., Devuyst, O., Eckardt, K.-U., Gansevoort, R. T., Harris, T., Horie, S., Kasiske, B. L., Odland, D., Pei, Y., Perrone, R. D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.59 · Cited by 611
Self-citation
Metadata
- Authors
- Irazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., Hogan, M. C., El-Zoghby, Z. M., Harris, P. C., Erickson, B. J., King, B. F., & Torres, V. E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2015-01
- Volume
- 26
- Issue
- 1
- Pages
- 160-172
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2101067234
- Cited by
- 625
- References
- 33
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.